KaloBios KB001-A fails Phase 2 study and discontinues development of KB001-A in cystic fibrosis

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this … Continued

Drug developed at University of Pittsburg proves effective against antibiotic-resistant ‘superbugs’

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called “superbugs” resistant to almost all existing antibiotics, which plague hospitals and … Continued

NovaBiotics Receives Orphan Drug Status from the FDA for Lynovex for the Treatment of Cystic Fibrosis

NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for Lynovex® (NM001), the Company’s first-in-class  therapeutic candidate for the treatment of Cystic Fibrosis (CF). CF is a … Continued

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Background Consensus guidelines recommend early treatment to eradicate newly acquired Pseudomonas aeruginosa (Pa) infection in cystic fibrosis (CF) patients although there is no single preferred regimen. Aztreonam for inhalation solution (AZLI) significantly reduces sputum Pa density in CF patients with chronic Pa infection and has been … Continued

Agile Sciences has $1.5 million NIH grant to help develop its cystic fibrosis therapy derived from sea sponges

Raleigh biotechnology company Agile Sciences has landed a $1.5 million National Institutes of Health grant to help develop its cystic fibrosis therapy derived from sea sponges. Agile was spun out of North Carolina State University with the help of a $30,000 startup … Continued

Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis Read more: http://www.digitaljournal.com/pr/1932533#ixzz32lRdzFo3

Laurent Pharmaceuticals Inc. announced today that the Research Institute of the McGill University Health Centre (RI-MUHC) has started enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with … Continued